ChiCTR1900024885 版本V1.4 版本创建时间2020/05/13 17:15:20 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR1900024885 

最近更新日期:

Date of Last Refreshed on:

2020-05-11 10:15:46 

注册时间:

Date of Registration:

2019-08-02 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

颅内床突旁动脉瘤治疗多中心登记观察研究(CAUSE)

Public title:

China Multi-center registration observational study for paraclinoid aneurysm treatment(CAUSE)

注册题目简写:

English Acronym:

研究课题的正式科学名称:

颅内床突旁动脉瘤治疗多中心登记观察研究(CAUSE)

Scientific title:

China Multi-center registration observational study for paraclinoid aneurysm treatment(CAUSE)

研究课题代号(代码):

Study subject ID:

No. 81771233; 2018-2-2041

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘爱华、彭飞 

研究负责人:

缪中荣 

Applicant:

Aihua Liu, Fei Peng 

Study leader:

Zhongrong Miao 

申请注册联系人电话:

Applicant telephone:

+86 18401657289

研究负责人电话:

Study leader's
telephone:

+86 010-59978857

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

18401657289@163.com

研究负责人电子邮件:

Study leader's E-mail:

15901398688@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国北京市丰台区樊羊路119号

研究负责人通讯地址:

中国北京市丰台区樊羊路119号

Applicant address:

119 South Fourth Ring Road West, Fengtai District, Beijing, China

Study leader's address:

119 South Fourth Ring Road West, Fengtai District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

100050

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

首都医科大学附属北京天坛医院

Applicant's institution:

Beijing Tiantan Hospital, Capital Medical University

研究负责人所在单位:

首都医科大学附属北京天坛医院

Affiliation of the Leader:

Beijing Tiantan Hospital, Capital Medical University

是否获伦理委员会批准:

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

首都医科大学附属北京天坛医院

Primary sponsor:

Beijing Tiantan Hospital, Capital Medical University

研究实施负责(组长)单位地址:

中国北京市丰台区樊羊路119号

Primary sponsor's address:

119 South Fourth Ring Road West, Fengtai District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京天坛医院

具体地址:

中国北京市丰台区樊羊路119号

Institution
hospital:

Beijing Tiantan Hospital, Capital Medical University

Address:

119 South Fourth Ring Road West, Fengtai District, Beijing, China

经费或物资来源:

国家自然科学基金;首都卫生发展专项

Source(s) of funding:

National Natural Science Foundation(No. 81771233), and Specific Research Projects for Capital Health Development (2018-2-2041).

研究疾病:

床突旁动脉瘤  

Target disease:

paraclinoid aneurysm

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

通过对床突旁动脉瘤不同治疗方式的预后进行数据分析对比,找出影响预后的相关因素,并建立床突旁动脉瘤治疗预后的评分系统,同时通过随访各种治疗方式的并发症情况,运用生存分析(并发症)明确哪种方式患者更能受益,对于有眼动脉症状的患者,明确哪种治疗方式更有利于患者远期症状解除,最终探索出不同类型动脉瘤的适宜治疗方式。  

Objectives of Study:

By analysing and comparing the effects by different treatments of paraclinoid aneurysms, we can find out the risk factors of poor prognosis, and establish a scoring system for the prognosis of the paraclinoid aneurysms. By analysing the information of the complications by different treatment methods in follow-up periods, we can carry out survival analysis to determine which method is more beneficial to patients. For patients with ocular symptoms, we aimed to find out which treatment is more conducive to symptomatic relief in the long-term follow-up. Finally, to explore the appropriate treatment for different types of paraclinoid aneurysms.

药物成份或治疗方案详述:

1)支架辅助弹簧圈栓塞 2)密网支架 3)其它治疗方式:单纯弹簧圈栓塞+球囊辅助弹簧圈栓塞 

Description for medicine or protocol of treatment in detail:

1. stent-assisted coiling; 2. flow diverter (FD) stents; 3. other treatments like coiling or balloon-assisted coiling etc. 

纳入标准:

1.所有囊性床突旁颅内动脉瘤患者,≥18岁;
2.患者血管三维影像资料完整(DSA、CTA、MRA等),临床信息完整。

Inclusion criteria

1. All patients with saccular paraclinoid intracranial aneurysms, patients >=18 years old;
2. The patient's imaging data and the clinical information should be complete.

排除标准:

1.梭型动脉瘤、夹层动脉瘤、假性动脉瘤等非囊性动脉瘤。
2. 合并其他脑血管疾病,如AVM, DAVF, MoyaMoya Disease等或合并脑肿瘤。
3. 随访缺失;临床、影像资料丢失。

Exclusion criteria:

1. Non-saccular aneurysms such as fusiform aneurysms, dissecting aneurysms, and pseudoaneurysms;
2. Coexist other cerebrovascular diseases such as AVM, DAVF, MoyaMoya Disease, etc. or with brain tumors;
3. Lost follow-up; clinical and imaging data were incomplete.

研究实施时间:

Study execute time:

From 2020-01-01 00:00:00 To 2025-01-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-01-01 00:00:00 To 2024-01-01 00:00:00

干预措施:

Interventions:

组别:

支架辅助组

样本量:

2000

Group:

stent-assisted group

Sample size:

干预措施:

支架辅助弹簧圈

干预措施代码:

Intervention:

stent-assisted coiling

Intervention code:

组别:

密网支架组

样本量:

2000

Group:

compacted group

Sample size:

干预措施:

密网支架

干预措施代码:

Intervention:

compacted stent

Intervention code:

组别:

保守观察组

样本量:

2000

Group:

Conservative group

Sample size:

干预措施:

保守观察

干预措施代码:

Intervention:

Conservative treatment

Intervention code:

组别:

其它干预组

样本量:

2000

Group:

Other treatments group

Sample size:

干预措施:

弹簧圈栓塞、球囊辅助栓塞等

干预措施代码:

Intervention:

coiling, balloon-assisted group. etc.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京天坛医院 

单位级别:

三级甲等 

Institution
hospital:

Beijing Tiantan Hospital

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京医院 

单位级别:

三级甲等 

Institution
hospital:

Beijing Hospital

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

黑龙江 

市(区县):

 

Country:

China

Province:

Helongjiang

City:

单位(医院):

哈尔滨医科大学附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Harbin Medical University

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

河北 

市(区县):

 

Country:

China

Province:

Hebei

City:

单位(医院):

河北省医科大学第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Hospital of Hebei Medical University

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

河北 

市(区县):

 

Country:

China

Province:

Hebei

City:

单位(医院):

河北省医科大学第二医院 

单位级别:

三级甲等 

Institution
hospital:

The Second Hospital of Hebei Medical University

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

天津 

市(区县):

 

Country:

China

Province:

Tianjin

City:

单位(医院):

天津环湖医院 

单位级别:

三级甲等 

Institution
hospital:

Tianjin Huanhu Hospital

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

山东 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

山东大学齐鲁医院 

单位级别:

三级甲等 

Institution
hospital:

Qilu Hospital of Shandong University

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

南方医科大学珠江医院 

单位级别:

三级甲等 

Institution
hospital:

Southern Medical University Zhujiang Hospital

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

四川 

市(区县):

 

Country:

China

Province:

Sichuan

City:

单位(医院):

西南医科大学附属医院 

单位级别:

三级甲等 

Institution
hospital:

Southwest Medical University Affiliated Hospital

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

中国人民解放军总医院 

单位级别:

三级甲等 

Institution
hospital:

The General Hospital of the People's Liberation Army

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

中国人民解放军东部战区总医院 

单位级别:

三级甲等 

Institution
hospital:

General Hospital of the Eastern Theater of the Chinese People's Liberation Army

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

吉林 

市(区县):

 

Country:

China

Province:

Jilin

City:

单位(医院):

吉林大学第一附属医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Jilin University

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

广西壮族自治区 

市(区县):

 

Country:

China

Province:

Guangxi Zhuang Autonomous Region

City:

单位(医院):

广西医科大学第一附属医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Guangxi Medical University

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

四川 

市(区县):

 

Country:

China

Province:

Sichuan

City:

单位(医院):

四川大学华西医院 

单位级别:

三级甲等 

Institution
hospital:

West China Hospital,Sichuan University

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京大学国际医院 

单位级别:

三级甲等 

Institution
hospital:

Peking University international hospital

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

河南 

市(区县):

 

Country:

China

Province:

He'nan

City:

单位(医院):

河南省人民医院 

单位级别:

三级甲等 

Institution
hospital:

Henan Provincial People's Hospital

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

辽宁 

市(区县):

 

Country:

China

Province:

Liaoning

City:

单位(医院):

中国医科大学第一附属医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of China Medical University

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

湖南 

市(区县):

 

Country:

China

Province:

Hu'nan

City:

单位(医院):

中南大学湘雅医院 

单位级别:

三级甲等 

Institution
hospital:

XiangYa Hospital CentralSouth University

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

河南 

市(区县):

 

Country:

China

Province:

He'nan

City:

单位(医院):

郑州大学第一附属医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Zhengzhou University

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

山西 

市(区县):

 

Country:

China

Province:

Shanxi

City:

单位(医院):

山西医科大学第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Hospital of Shanxi Medical University

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

陕西 

市(区县):

 

Country:

China

Province:

Shaanxi

City:

单位(医院):

西安交通大学第一附属医院 

单位级别:

三级甲等 

Institution
hospital:

First Affiliated Hospital of Xi'an Jiaotong University

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

新疆维吾尔自治区 

市(区县):

 

Country:

China

Province:

Xinjiang Uygur Autonomous Region

City:

单位(医院):

新疆医科大学第一附属医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Xinjiang Medical University

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

福建 

市(区县):

 

Country:

China

Province:

Fujian

City:

单位(医院):

福建医科大学第一附属医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Fujian Medical University

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

广东省人民医院 

单位级别:

三级甲等 

Institution
hospital:

Guangdong Provincial People's Hospital

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

天津 

市(区县):

 

Country:

China

Province:

Tianjin

City:

单位(医院):

天津医科大学总医院 

单位级别:

三级甲等 

Institution
hospital:

Tianjin Medical University General Hospital

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

新的神经功能缺损

指标类型:

主要指标

Outcome:

new neurological defect

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

再破裂

指标类型:

主要指标

Outcome:

rerupture

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

再通

指标类型:

主要指标

Outcome:

recanalization

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

需再次手术干预

指标类型:

主要指标

Outcome:

required additional intervention

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

观察性研究,前瞻性队列研究,无需随机化方案干预

Randomization Procedure (please state who generates the random number sequence and by what method):

Observational study, prospective cohort study, no need for randomized intervention

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

N/A

Blinding:

N/A

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验结束后6个月内在公共数据平台ResMan实现共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Raw data will be shared with the public on Public data platform (ResMan) within 6 month after the trial is finished.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据原始记录、病例记录表采用CRF表数据库形式永久保存,同时将数据录入公共数据平台ResMan和Excel电子数据库进行保存。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Raw data will be saved as CRF, Public data platform (ResMan) and Excel data base.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2019-08-02 15:01:02